Story Summary: In a study in mice, the team of researchers from Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences at Tufts, and Tufts Medical Center report that inhibiting ROCK, or Rho-associated kinase, in the earliest stages of breast cancer decreased metastatic tumor mass in bone by 77 percent and overall frequency of metastasis by 36 percent. The results suggest that ROCK may be a target for new drug therapies to reduce breast cancer metastasis. We also found that using shRNA short hairpin RNA to knock down ROCK expression slowed metastasis. Bone is the most common site of breast cancer metastasis, affected three times more often than the lungs or liver. The study, published online in advance of print, will appear in the November 15 issue of Cancer Research. The results were also presented at the Frontiers in Basic Cancer Research conference, held by the American Association for Cancer Research in October. Coauthors include Robert H. Goldstein, a student in the MD/PhD program at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences; and Ellen M. Scepansky, MD, hematology and oncology fellow at Tufts Medical Center and clinical instructor in the department of medicine at Tufts University School of Medicine. CAN-09-1541About Tufts University School of MedicineTufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. The Sackler School undertakes research that is consistently rated among the highest in the nation for its impact on the advancement of medical science. The Sackler School undertakes research that is consistently rated among the highest in the nation for its impact on the advancement of medical science….Read the Full Story
ADVERTISMENT
ADVERTISMENT
Experimental agent reduces breast cancer metastasis to bone
Posted on 05 November 2009 - 15:38 by Alfie
Related posts:
ADVERTISMENT
Custom Search
2 Comments For This Post
Leave a Reply
ADVERTISMENT
 | This site complies with the HONcode standard for trustworthy health information: verify here. |
Member
-
Perspective
-
Confidentiality
-
Disclosure
-
Reliability
-
Courtesy
-
ADVERTISMENT
Compare prices on home medical supplies. Search from all your favorite stores and shop online to find medicine & remedies, vitamins, or even health & fitness books. Browse thousands of products in categories such as allergy & sinus Medicine, vitamins & nutrition and home tests to find the lowest prices.
Technorati Profile
Dmegs Web Directory
November 12th, 2009 at 23:15
Cancer is a disease more difficult to address because the symptoms of this disease but I am very painful but there are medications that may be satisfactory to subtract against that disease symptoms such vicodin I take a drug that is very good at these cases.
November 27th, 2009 at 07:19
Breast cancer is the second leading fatal cancer in women, and affects just under one in eight women in the United States. Bone is the most common site of breast cancer metastasis, affected three times more often than the lungs or liver. In this case ROCK is very useful to reduce metastasis from bone.